High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: A pilot study

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 291-298

  Onitilo, Adedayo A ^a,b   Engel, Jessica M ^a   Stankowski, Rachel V ^a   Liang, Hong ^a   Berg, Richard L ^a   Doi, Suhail A R ^b  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antibodies, Monoclonal therapeutic use; Breast neoplasms metabolism mortality; Heart diseases chemically induced; hs CRP; Receptor, HER2

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; TRASTUZUMAB; TROPONIN I;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FALSE POSITIVE RESULT; FEMALE; HEALTH CARE COST; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BREAST NEOPLASMS; C-REACTIVE PROTEIN; FEMALE; HEART DISEASES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; PROSPECTIVE STUDIES; ROC CURVE; STROKE VOLUME; TROPONIN I; VENTRICULAR FUNCTION, LEFT;

EID: 84863981524     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2039-z     Document Type: Article

References (37)

1. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D
2. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D
3. RB Costa G Kurra L Greenberg CE Geyer 2010 Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer Ann Oncol 21 2153 2160 20351072 10.1093/annonc/mdq096 1:STN:280:DC%2BC3cbhtl2htw%3D%3D
4. GA Viani SL Afonso EJ Stefano LI De Fendi FV Soares 2007 Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 153 17686164 10.1186/1471-2407-7-153
5. AJ Chien HS Rugo 2010 The cardiac safety of trastuzumab in the treatment of breast cancer Expert Opin Drug Saf 9 335 346 20175700 10.1517/ 14740331003627441 1:CAS:528:DC%2BC3cXisVCgtrk%3D
6. HC Routledge DW Rea RP Steeds 2006 Monitoring the introduction of new drugs-Herceptin to cardiotoxicity Clin Med 6 478 481 17080896 1:STN:280:DC%2BD28nkslCisA%3D%3D
7. D Tripathy DJ Slamon M Cobleigh A Arnold M Saleh JE Mortimer M Murphy SJ Stewart 2004 Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression J Clin Oncol 22 1063 1070 15020607 10.1200/JCO.2004.06.557 1:CAS:528:DC%2BD2cXptlCku78%3D
8. MS Ewer MT Vooletich JB Durand ML Woods JR Davis V Valero DJ Lenihan 2005 Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 7820 7826 16258084 10.1200/JCO.2005.13.300 1:CAS:528:DC%2BD2MXht1Cqs7bP
9. A Seidman C Hudis MK Pierri S Shak V Paton M Ashby M Murphy SJ Stewart D Keefe 2002 Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 1215 1221 11870163 10.1200/JCO.20.5.1215 1:CAS:528: DC%2BD38XisVWmuro%3D
10. R Kazanegra V Cheng A Garcia P Krishnaswamy N Gardetto P Clopton A Maisel 2001 A rapid test for B-type natriuretuc peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study J Card Fail 7 21 29 11264546 10.1054/jcaf.2001.23355 1:CAS:528: DC%2BD3MXivVOms7w%3D
11. P Krishnaswamy E Lubien P Clopton J Koon R Kazanegra R Wanner N Gardetto A Garcia A DeMaria AS Maisel 2001 Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction Am J Med 111 274 279 11566457 10.1016/S0002-9343(01)00841-5 1:CAS:528: DC%2BD3MXmvVKrtLg%3D
12. D Cardinale MT Sandri A Martinoni E Borghini M Civelli G Lamantia S Cinieri G Martinelli C Fiorentini CM Cipolla 2002 Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy Ann Oncol 13 710 715 12075738 10.1093/annonc/mdf170 1:STN:280:DC%2BD38zjtlWrsA%3D%3D
13. E Lubien A DeMaria P Krishnaswamy P Copton J Koon R Kazanegra N Gardetto E Wanner AS Maisel 2002 Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings Circulation 105 595 601 11827925 10.1161/hc0502.103010 1:CAS:528:DC%2BD38XhslGgs78%3D
14. MT Sandri D Cardinale L Zorzino R Passerini P Lentati A Martinoni G Martinenlli CM Cipolla 2003 Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy Clin Chem 49 248 252 12560347 10.1373/49.2.248 1:CAS:528:DC%2BD3sXptVGisQ%3D%3D
15. C Xue Y Feng J Wo Y Li 2006 Prognostic value of high-sensitivity C-reactive protein in patients with chronic heart failure N Z Med J 119 U2314 17146489
16. D Giannessi C Colotti M Maltinti S Del Ry C Prontera S Turchi A Labbate D Neglia 2007 Circulating heat shock proteins and inflammatory markers in patients with idiopathic left ventricular dysfunction: their relationships with myocardial and microvascular impairment Cell Stress Chaperones 12 265 274 17915559 10.1379/CSC-272.1 1:CAS:528:DC%2BD2sXhtFKntLbM
17. WH Tang K Shrestha F Van Lente RW Troughton MG Martin AG Borowski S Jasper AL Klein 2008 Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure Am J Cardiol 101 370 373 18237602 10.1016/j.amjcard.2007.08.038 1:CAS:528:DC%2BD1cXhsVSmsL8%3D
18. TA Pearson GA Mensah RW Alexander JL Anderson RO Cannon III M Criqui YY Fadl SP Fortmann Y Hong GL Myers N Rifai SC Smith Jr K Taubert RP Tracy F Vinicor Centers for Disease Control and Prevention; American Heart Association 2003 Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 499 511 12551878 10.1161/01.CIR.0000052939.59093.45
19. C Heeschen CW Hamm B Goldmann A Deu L Langenbrink HD White 1999 Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management Lancet 354 1757 1762 10577636 10.1016/S0140-6736(99)10285-X 1:CAS:528:DC%2BD3cXhtVam
20. E Tan-Chiu G Yothers E Romond CE Geyer Jr M Ewer D Keefe RP Shannon SM Swain A Brown L Fehrenbacher VG Vogel TE Seay P Rastogi EP Mamounas N Wolmark J Bryant 2005 Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 7811 7819 16258083 10.1200/JCO.2005.02.4091 1:CAS:528:DC%2BD2MXht1Cqs7bN
21. JA Chapman D Meng L Shepherd W Parulekar JN Ingle HB Muss M Palmer C Yu PE Goss 2008 Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer J Natl Cancer Inst 100 252 260 18270335 10.1093/jnci/djn014
22. PM Ridker CH Hennekens JE Buring N Rifai 2000 C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 836 843 10733371 10.1056/NEJM200003233421202 1:CAS:528:DC%2BD3cXisVensrs%3D
23. AM Arruda-Olson M Enriquez-Sarano F Bursi SA Weston AS Jaffe JM Killian VL Roger 2010 Left ventricular function and C-reactive protein levels in acute myocardial infarction Am J Cardiol 105 917 921 20346306 10.1016/j.amjcard.2009. 11.025 1:CAS:528:DC%2BC3cXjvFCisLY%3D
24. R Arroyo-Espiliguero P Avanzas J Quiles JC Kaski 2009 Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease Atherosclerosis 204 239 243 10.1016/j.atherosclerosis. 2008.08.009
25. JD Windram PH Loh AS Rigby I Hanning AL Clark JG Cleland 2007 Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure Am Heart J 153 1048 1055 17540208 10.1016/j.ahj.2007.03.044 1:CAS:528:DC%2BD2sXmtVaqs78%3D
26. T Tsuruda J Kato T Sumi K Mishima H Masuyama H Nakao T Imamura T Eto K Kitamura 2007 Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus Vasc Health Risk Manag 3 417 423 17969372 1:CAS:528:DC%2BD2sXht1aqtbfE
27. G Ndrepepa A Kastrati S Braun J Mehilli K Niemöller N von Beckerath O von Beckerath W Vogt A Schömig 2006 N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease Am J Med 119 355 e1 e8 16564781
28. C Ishikawa T Tsutamoto M Fujii H Sakai T Tanaka M Horie 2006 Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy Circ J 70 857 863 16799238 10.1253/circj.70.857 1:CAS:528:DC%2BD28XnsVWjt7s%3D
29. LA Kutteh T Hobday A Jaffe B LaPlant D Hillman P Kaufman N Davidson S Martino A Moreno E Perez Central Cancer Treatment Group 2007 A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer J Clin Oncol 25 18 579
30. S Goel RJ Simes JM Beith 2011 Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer Asia Pac J Clin Oncol 7 276 280 21884439 10.1111/j.1743-7563.2011.01422.x
31. N Fallah-Rad JR Walker A Wassef M Lytwyn S Bohonis T Fang G Tian ID Kirkpatrick PK Singal M Krahn D Grenier DS Jassal 2011 The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with trastuzumab therapy J Am Coll Cardiol 57 2263 2270 21616287 10.1016/j.jacc.2010. 11.063 1:CAS:528:DC%2BC3MXot1yjsbg%3D
32. H Sawaya IA Sebag JC Plana JL Januzzi B Ky V Cohen S Gosavi JR Carver SE Wiegers RP Martin MH Picard RE Gerszten EF Halpern J Passeri I Kuter M Scherrer-Crosbie 2011 Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 1375 1380 21371685 10.1016/j.amjcard.2011.01.006 1:CAS:528:DC%2BC3MXkvVWgtrY%3D
33. D Cardinale A Colombo R Torrisi MT Sandri M Civelli M Salvatici G Lamantia N Colombo S Cortinovis MA Dessanai F Nolè F Veglia CM Cipolla 2010 Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 3910 3916 20679614 10.1200/JCO.2009.27. 3615 1:CAS:528:DC%2BC3cXht1eqsb%2FJ
34. PG Morris C Chen R Steingart M Fleisher N Lin B Moy S Come S Sugarman A Abbruzzi R Lehman S Patil M Dickler HL McArthur E Winer L Norton CA Hudis CT Dang 2011 Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib Clin Cancer Res 17 3490 3499 21372222 10.1158/1078-0432.CCR-10-1359 1:CAS:528:DC%2BC3MXmtVGitLs%3D
35. A Mosterd AW Hoes MC de Bruyne JW Deckers DT Linker A Hofman DE Grobbee 1999 Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study Eur Heart J 20 447 455 10213348 10.1053/euhj.1998.1239 1:STN:280:DyaK1M3ivVelsA%3D%3D
36. RS Vasan MG Larson EJ Benjamin JC Evans CK Reiss D Levy 1999 Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort J Am Coll Cardiol 33 1948 1955 10362198 10.1016/S0735-1097(99)00118-7 1:STN:280: DyaK1M3ovFSntg%3D%3D
37. JS Gottdiener RL McClelland R Marshall L Shemanski CD Furberg DW Kitzman M Cushman J Polak JM Gardin BJ Gersh GP Aurigemma TA Manolio 2002 Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study Ann Intern Med 137 631 639 12379062